- Home
- MYGN vs THRM Comparison
MYGN vs THRM Comparison
Compare MYGN & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- THRM
- Stock Information
- Founded
- MYGN 1991
- THRM 1991
- Country
- MYGN United States
- THRM United States
- Employees
- MYGN N/A
- THRM N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- THRM Auto Parts:O.E.M.
- Sector
- MYGN Health Care
- THRM Consumer Discretionary
- Exchange
- MYGN Nasdaq
- THRM Nasdaq
- Market Cap
- MYGN 744.7M
- THRM 1.0B
- IPO Year
- MYGN 1995
- THRM 1993
- Fundamental
- Price
- MYGN $5.21
- THRM $30.17
- Analyst Decision
- MYGN Hold
- THRM Buy
- Analyst Count
- MYGN 15
- THRM 3
- Target Price
- MYGN $15.14
- THRM $50.33
- AVG Volume (30 Days)
- MYGN 1.3M
- THRM 282.2K
- Earning Date
- MYGN 08-05-2025
- THRM 07-24-2025
- Dividend Yield
- MYGN N/A
- THRM N/A
- EPS Growth
- MYGN N/A
- THRM 10.20
- EPS
- MYGN N/A
- THRM 1.59
- Revenue
- MYGN $831,300,000.00
- THRM $1,453,963,000.00
- Revenue This Year
- MYGN N/A
- THRM N/A
- Revenue Next Year
- MYGN $6.68
- THRM $4.04
- P/E Ratio
- MYGN N/A
- THRM $18.99
- Revenue Growth
- MYGN 7.38
- THRM N/A
- 52 Week Low
- MYGN $3.81
- THRM $22.75
- 52 Week High
- MYGN $29.30
- THRM $56.68
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- THRM 59.32
- Support Level
- MYGN $4.90
- THRM $29.57
- Resistance Level
- MYGN $5.83
- THRM $31.52
- Average True Range (ATR)
- MYGN 0.28
- THRM 1.02
- MACD
- MYGN 0.04
- THRM 0.11
- Stochastic Oscillator
- MYGN 54.21
- THRM 66.67
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About THRM Gentherm Inc
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.